Clinical-stage biopharmaceutical company developing inhaled therapies for serious pulmonary diseases and central nervous system disorders
Clinical-stage biopharmaceutical company developing inhaled therapies for serious pulmonary diseases and central nervous system disorders. Its proprietary iSPERSE engineered dry-powder platform delivers respiratory and non-respiratory therapies through the respiratory system, aiming to increase local drug concentrations and reduce systemic side effects. Pipeline areas include allergic bronchopulmonary aspergillosis, COPD, and acute migraine.